Little is known about confounding factors influencing Alzheimer's disease (AD) blood biomarker concentrations.
Objective
The objective of this systematic review was to explore the available evidence for the influences of ethnicity and race on AD blood biomarker concentrations.
Methods
We conducted a comprehensive systematic search in PubMed and Web of Science databases spanning from inception until 15 June 2023. We included studies that utilized plasma or serum biomarkers (amyloid-β [Aβ], total tau [t-tau], phosphorylated tau [p-tau], neurofilament light [NfL], and glial fibrillary acidic protein [GFAP]), compared individuals with AD to healthy controls, and included a minimum of two ethnic or racial groups for comparison. A total of 10 studies were included in the qualitative synthesis. All studies were conducted in the US.
Results
Seven studies reported differences in blood biomarker concentrations between ethnic or racial groups. However, after adjusting for medical conditions and social determinants of health, the differences became non-significant in two of the studies. The included studies differed in their included covariates and their statistical approaches, which complicated the interpretation of the observed differences.
Conclusions
The available evidence suggests that ethnicity and race may influence blood biomarker concentrations. However, it remains unclear to what extent these differences are mediated by differences in social determinants of health and medical conditions. Future studies are needed to explore ethnic and racial differences in blood biomarkers, including studies in diverse samples outside the US.
TeunissenCEVerberkIMWThijssenEH, et al.Blood-based biomarkers for Alzheimer's disease: towards clinical implementation. Lancet Neurol2022; 21: 66–77.
2.
HanssonOEdelmayerRMBoxerAL, et al.The Alzheimer's association appropriate use recommendations for blood biomarkers in Alzheimer's disease. Alzheimers Dement2022; 18: 2669–2686.
3.
LeuzyAMattsson-CarlgrenNPalmqvistS, et al.Blood-based biomarkers for Alzheimer's disease. EMBO Mol Med2022; 14: e14408.
4.
BrandALLawlerPEBollingerJG, et al.The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer's disease: a literature review. Alzheimers Res Ther2022; 14: 195.
5.
SalvadóGOssenkoppeleRAshtonNJ, et al.Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads. EMBO Mol Med2023; 15: e17123.
6.
AguillonDLangellaSChenY, et al.Plasma p-tau217 predicts in vivo brain pathology and cognition in autosomal dominant Alzheimer's disease. Alzheimers Dement2023; 19: 2585–2594.
7.
Mattsson-CarlgrenNSalvadóGAshtonNJ, et al.Prediction of longitudinal cognitive decline in preclinical Alzheimer disease using plasma biomarkers. JAMA Neurol2023; 80: 360–369.
8.
PalmqvistSStomrudECullenN, et al.An accurate fully automated panel of plasma biomarkers for Alzheimer's disease. Alzheimers Dement2023; 19: 1204–1215.
9.
Gilmore-BykovskyiALJinYGleasonC, et al.Recruitment and retention of underrepresented populations in Alzheimer's disease research: a systematic review. Alzheimers Dement (N Y)2019; 5: 751–770.
10.
FranzenSSmithJEvan den BergE, et al.Diversity in Alzheimer's disease drug trials: the importance of eligibility criteria. Alzheimers Dement2022; 18: 810–823.
11.
KarikariTK. Blood tests for Alzheimer's disease: increasing efforts to expand and diversify research participation is critical for widespread validation and acceptance. J Alzheimers Dis2022; 90: 967–974.
12.
ChaudhryARizigM. Comparing fluid biomarkers of Alzheimer's disease between African American or black African and white groups: a systematic review and meta-analysis. J Neurol Sci2021; 421: 117270.
13.
ModesteESPingLWatsonCM, et al.Quantitative proteomics of cerebrospinal fluid from African Americans and caucasians reveals shared and divergent changes in Alzheimer's disease. Mol Neurodegener2023; 18: 48.
14.
GleasonCEZuelsdorffMGoodingDC, et al.Alzheimer's disease biomarkers in Black and non-Hispanic White cohorts: a contextualized review of the evidence. Alzheimers Dement2022; 18: 1545–1564.
15.
LebrunLHanseeuwBvan PeschV, et al.Alzheimer disease's cerebrospinal fluid biomarkers differences between immigrants and natives in a Belgian memory clinic. Acta Neurol Belg2023; 123: 537–544.
16.
QinWLiWWangQ, et al.Race-related association between APOE genotype and Alzheimer's disease: a systematic review and meta-analysis. J Alzheimers Dis2021; 83: 897–906.
17.
Le GuenYRaulinACLogueMW, et al.Association of African ancestry-specific APOE missense variant R145C with risk of Alzheimer disease. JAMA2023; 329: 551–560.
18.
EvansWFungHCSteeleJ, et al.The tau H2 haplotype is almost exclusively Caucasian in origin. Neurosci Lett2004; 369: 183–185.
19.
KauweJSCruchagaCMayoK, et al.Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition. Proc Natl Acad Sci U S A2008; 105: 8050–8054.
20.
HowellJCWattsKDParkerMW, et al.Race modifies the relationship between cognition and Alzheimer's disease cerebrospinal fluid biomarkers. Alzheimers Res Ther2017; 9: 88.
21.
MorrisJCSchindlerSEMcCueLM, et al.Assessment of racial disparities in biomarkers for Alzheimer disease. JAMA Neurol2019; 76: 264–273.
22.
SyrjanenJACampbellMRAlgeciras-SchimnichA, et al.Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities. Alzheimers Dement2022; 18: 1128–1140.
23.
Pichet BinetteAJanelidzeSCullenN, et al.Confounding factors of Alzheimer's disease plasma biomarkers and their impact on clinical performance. Alzheimers Dement2023; 19: 1403–1414.
24.
SimonsenAHGleerupHSMusaeusCS, et al.Neurofilament light chain levels in serum among a large mixed memory clinic cohort: confounders and diagnostic usefulness. Alzheimers Dement (Amst)2023; 15: e12512.
25.
RosselliMUribeIVAhneE, et al.Culture, ethnicity, and level of education in Alzheimer's disease. Neurotherapeutics2022; 19: 26–54.
26.
MayedaERGlymourMMQuesenberryCP, et al.Inequalities in dementia incidence between six racial and ethnic groups over 14 years. Alzheimers Dement2016; 12: 216–224.
27.
GreenRCCupplesLAGoR, et al.Risk of dementia among white and African American relatives of patients with Alzheimer disease. JAMA2002; 287: 329–336.
28.
CooperCTandyARBalamuraliTB, et al.A systematic review and meta-analysis of ethnic differences in use of dementia treatment, care, and research. Am J Geriatr Psychiatry2010; 18: 193–203.
29.
ChinALNegashSHamiltonR. Diversity and disparity in dementia: the impact of ethnoracial differences in Alzheimer disease. Alzheimer Dis Assoc Disord2011; 25: 187–195.
30.
Ma'uECullumSCheungG, et al.Differences in the potential for dementia prevention between major ethnic groups within one country: a cross sectional analysis of population attributable fraction of potentially modifiable risk factors in New Zealand. Lancet Reg Health West Pac2021; 13: 100191.
31.
MukadamNMarstonLLewisG, et al.South Asian, black and white ethnicity and the effect of potentially modifiable risk factors for dementia: a study in English electronic health records. PLoS One2023; 18: e0289893.
32.
ChenCZissimopoulosJM. Racial and ethnic differences in trends in dementia prevalence and risk factors in the United States. Alzheimers Dement (N Y)2018; 4: 510–520.
33.
McGrathRPSnihSAMarkidesKS, et al.The burden of health conditions across race and ethnicity for aging Americans: disability-adjusted life years. Medicine (Baltimore)2019; 98: e17964.
34.
TeagleWLNorrisETRishishwarL, et al.Comorbidities and ethnic health disparities in the UK biobank. JAMIA Open2022; 5: ooac057.
35.
AkinbamiLJChenT-CDavyO, et al.National health and nutrition examination survey, 2017–march 2020 prepandemic file: sample design, estimation, and analytic guidelines. Vital Health Stat2022; (190): 1–36.
36.
LivingstonGSommerladAOrgetaV, et al.Dementia prevention, intervention, and care. Lancet2017; 390: 2673–2734.
37.
LivingstonGHuntleyJSommerladA, et al.Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet2020; 396: 413–446.
38.
MoherDLiberatiATetzlaffJ, et al.Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med2009; 6: e1000097.
39.
WhitingPFRutjesAWWestwoodME, et al.QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med2011; 155: 529–536.
40.
YamashitaKMiuraMWatanabeS, et al.Fully automated and highly specific plasma β-amyloid immunoassays predict β-amyloid status defined by amyloid positron emission tomography with high accuracy. Alzheimers Res Ther2022; 14: 86.
41.
CosentinoSASternYSokolovE, et al.Plasma β-amyloid and cognitive decline. Arch Neurol2010; 67: 1485–1490.
42.
LuchsingerJATangMXMillerJ, et al.Relation of plasma homocysteine to plasma amyloid beta levels. Neurochem Res2007; 32: 775–781.
43.
BrickmanAMManlyJJHonigLS, et al.Plasma p-tau181, p-tau217, and other blood-based Alzheimer's disease biomarkers in a multi-ethnic, community study. Alzheimers Dement2021; 17: 1353–1364.
44.
BrickmanAMManlyJJHonigLS, et al.Correlation of plasma and neuroimaging biomarkers in Alzheimer's disease. Ann Clin Transl Neurol2022; 9: 756–761.
45.
HallJRPetersenMJohnsonL, et al.Characterizing plasma biomarkers of Alzheimer's in a diverse community-based cohort: a cross-sectional study of the HAB-HD cohort. Front Neurol2022; 13: 871947.
46.
BarkerWQuinonezCGreigMT, et al.Utility of plasma neurofilament light in the 1Florida Alzheimer's disease research center (ADRC). J Alzheimers Dis2021; 79: 59–70.
47.
O'BryantSPetersenMHallJ, et al.Characterizing plasma NfL in a community-dwelling multi-ethnic cohort: results from the HABLE study. Alzheimers Dement2022; 18: 240–250.
48.
SchindlerSEKarikariTKAshtonNJ, et al.Effect of race on prediction of brain amyloidosis by plasma Aβ42/Aβ40, phosphorylated tau, and neurofilament light. Neurology2022; 99: e245–e257.
49.
RajanKBMcAninchEAAggarwalNT, et al.Longitudinal changes in blood biomarkers of clinical Alzheimer disease in a biracial population sample. Neurology2023; 100: e874–e883.
50.
GonzalesMMShortMISatizabalCL, et al.Blood biomarkers for dementia in hispanic and non-hispanic white adults. Alzheimers Dement (N Y)2021; 7: e12164.
51.
O'BryantSPetersenMHallJ, et al.Depression is differentially related to cognitive and biomarker outcomes among Mexican Americans. Front Psychiatry2022; 13: 901403.
52.
GarrettSLMcDanielDObideenM, et al.Racial disparity in cerebrospinal fluid amyloid and tau biomarkers and associated cutoffs for mild cognitive impairment. JAMA Netw Open2019; 2: e1917363.
53.
KoiniMPirpamerLHoferE, et al.Factors influencing serum neurofilament light chain levels in normal aging. Aging (Albany NY)2021; 13: 25729–25738.
54.
NielsenTR. Assessment in culturally, linguistically, and educationally diverse older populations in Europe. Am J Alzheimers Dis Other Demen2022; 37: 15333175221117006.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
